The authors conclude that atorvastatin is a safe and effective treatment for dyslipidemic patients with NAFLD that warrants testing in a multicenter, controlled clinical trial.

Atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of morbidity and mortality worldwide. Cardiovascular (CV) risk reduction is important in patients at high risk for a first ...